Gail McIntyre, Ph.D., DABT, the Chief Scientific Officer of Aravive (aravive.com), provides a thorough overview of Aravive’s important work researching and developing treatments for life-threatening diseases.
Gail McIntyre has a long history of successful accomplishments in the business arena. She served as principal at IntelliDev Consulting, LLC where she assisted multiple biotechnology companies as a senior consultant. She was VP of Development for Meryx, Inc., Senior Vice President of Research at Furiex Pharmaceuticals, Inc., and was the head of Pharmaceutical Product Development, LLC’s compound partnering business for many years before arriving at Aravive where she was Senior Vice President of Research and Development prior to becoming their CSO.
Dr. McIntyre talks about the innovative work they are doing at Aravive, such as developing treatments created specifically to halt the progression of life-threatening diseases, including cancer, fibrosis, and others. The Aravive system is predicated upon particular approaches to specifically target the signaling pathways that push the accelerated activation, migration, and ultimate invasion of abnormal cells into normal healthy tissues.
The scientific officer explains the complex finer points of Aravive’s top products in development. The AVB-500 is their lead product candidate, an ultra-high affinity decoy protein that specifically targets the GAS6/AXL signaling pathway. The AVB-500 starves the AXL pathway of its signal by capturing the circulating and bound GAS6, which can halt the biological processes that promote and accelerate the disease.
Dr. McIntyre provides an overview of how tumors fight to survive. She explains how tumors secrete interleukins, etc., that can have an impact on white cells. She details the processes that can work to enhance factors for tumor growth and advancement, allowing them to survive in less than ideal conditions. The science expert explains how they conduct studies on oncology drugs, observing GAS6 levels in monkeys. She further details how certain doses of drugs will suppress GAS6 levels in general, specifically studying ovarian cancer development.
Dr. McIntyre is the noted author of over 30 regulatory submissions and she is a board-certified toxicologist with considerable experience in many therapeutic areas such as oncology, infectious diseases, central nervous system issues, and much more.